Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | WNT3 | P56703 | 1/20 | 0.41 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.36 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31486522 | 1.00 | ACE (0.49) | ACECHRM2CHRM1CHRM3WNT3 | |
| SCHEMBL1256527 | 1.00 | ACE (0.49) | ACECHRM2CHRM1CHRM3WNT3 | |
| SCHEMBL713925 | 1.00 | ACE (0.49) | ACECHRM2CHRM1CHRM3WNT3 | |
| SCHEMBL926579 | 0.91 | HSD17B10 (0.43) | ACECHRM2CHRM1CHRM3WNT3 | |
| SCHEMBL9763240 | 0.91 | HSD17B10 (0.43) | ACECHRM2CHRM1CHRM3WNT3 | |
| SCHEMBL3617740 | 0.91 | HSD17B10 (0.43) | ACECHRM2CHRM1CHRM3WNT3 | |
| Propionaldehyde SCHEMBL6073504 | 0.90 | ACE (0.45) | ACECHRM2CHRM1CHRM3WNT3 | |
| SCHEMBL713924 | 0.87 | CHRM2 (0.41) | ACECHRM2CHRM1CHRM3WNT3 | |
| SCHEMBL12105456 | 0.87 | CHRM2 (0.41) | ACECHRM2CHRM1CHRM3WNT3 | |
| SCHEMBL20345647 | 0.87 | CHRM2 (0.41) | ACECHRM2CHRM1CHRM3WNT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235389-A1 | P53 MODULATORS | NESTED THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4522596-A1 | DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS | C4X Discovery Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119497712-A | Indane derivatives as MALT1 inhibitors | 希四克斯探索有限公司 | 2025-02-21 | — | — | CN | disclosed |
| WO-2024215802-A1 | BENZOFURANYL AND BENZOTHIENYL COMPOUNDS AS P53 MODULATORS | NESTED THERAPEUTICS, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2024-10-01 | — | — | US | disclosed |
| WO-2024140851-A1 | TOLL-LIKE RECEPTOR INHIBITOR, AND PREPARATION THEREFOR AND APPLICATION THEREOF | 上海维申医药有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-118215652-A | Substituted hydroxymethyl pyrrolidines and medical uses thereof | 阿托基公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-117964684-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964683-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023218203-A1 | DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS | C4X DISCOVERY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| EP-2857401-A1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | Meiji Seika Pharma Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| CN-104334559-A | Novel beta-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO LTD | 2015-02-04 | — | — | CN | disclosed |
| US-8835466-B2 | Synthesis and uses of pyroglutamic acid derivatives | PRODIMED, S.A. (ES) | 2014-09-16 | — | — | US | disclosed |
| US-20090163555-A1 | SYNTHESIS AND USES OF PYROGLUTAMIC ACID DERIVATIVES | PRODIMED, S.A. (ES) | 2009-06-25 | — | — | US | disclosed |
| US-20050148588-A1 | LFA-1 antagonist compounds | GENENTECH, INC. | 2005-07-07 | — | — | US | disclosed |
| US-6872735-B2 | LFA-1 antagonist compounds | GENENTECH, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| US-20040058968-A1 | LFA-1 antagonist compounds | GENENTECH, INC. | 2004-03-25 | — | — | US | disclosed |
| US-6667318-B2 | Antiinflammatory agents; autoimmune disease | GENENTECH, INC. | 2003-12-23 | — | — | US | disclosed |
| US-20020119994-A1 | LFA-1 Antagonist compounds | GENENTECH, INC | 2002-08-29 | — | — | US | disclosed |
| US-5021439-A | Senile dementia and memory dysfunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163555-A1 | SYNTHESIS AND USES OF PYROGLUTAMIC ACID DERIVATIVES | GLUL, RIMKLA, GLS | ACE 1578/4885CHRM2 4435/4885CHRM1 3897/4885 |
| US-20040058968-A1 | LFA-1 antagonist compounds | ICAM1, VCAM1, CD58 | ACE 3590/4885CHRM2 570/4885CHRM1 169/4885 |
| US-20020119994-A1 | LFA-1 Antagonist compounds | ICAM1, VCAM1, CD58 | ACE 3885/4885CHRM2 666/4885CHRM1 224/4885 |
| US-20050148588-A1 | LFA-1 antagonist compounds | CD58, VCAM1, ICAM1 | ACE 3701/4885CHRM2 418/4885CHRM1 164/4885 |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | ACE 1598/4885CHRM2 634/4885CHRM1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.